Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
Public ClinicalTrials.gov record NCT00060489. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT00060489
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- SEROQUEL (quetiapine fumarate) Tablets Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2002
- Primary completion
- Aug 31, 2003
- Completion
- Aug 31, 2003
- Last update posted
- Jan 25, 2011
2002 – 2003
United States locations
- U.S. sites
- 27
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Beverly Hills | California | — | — |
| Not listed | La Mesa | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | West Palm Beach | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Smyrna | Georgia | — | — |
| Not listed | Oak Brook | Illinois | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Clementon | New Jersey | — | — |
| Not listed | Moorestown | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Staten Island | New York | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Falls Church | Virginia | — | — |
| Not listed | Bellevue | Washington | — | — |
| Not listed | Kirkland | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00060489, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 25, 2011 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00060489 live on ClinicalTrials.gov.